Researchers study how doubling entire genomes affects cancer evolution

A study of 41,332 tumours shows how whole-genome doubling changes cancer progression and immune response.

Whole-genome doubling (WGD) is common in human cancers. It is linked to tumour progression and bad clinical outcomes.

Researchers analyzed 41,332 tumours from 12 cancer types. They used genomic analyses, evolutionary timing, and multi-omic data.

Whole-genome doubling (WGD) is when the entire genome doubles. Driver mutations and homologous recombination deficiency-associated mutagenesis generally happened before WGD.

Post-WGD chromosome-arm losses showed much less dependence on cancer type. These losses had 61-75% less variance explained by cancer type than pre-WGD losses.

WGD+ tumours showed reduced interferon-response and HLA antigen-presentation programmes. These changes are linked to epigenetic remodelling.

WGD acts as a recurrent evolutionary transition. It is associated with altered chromosomal evolution and epigenetically linked immune adaptation.

Key facts

  • WGD is associated with tumour progression and adverse clinical outcomes.
  • Post-WGD chromosome-arm losses showed 61-75% less variance explained by cancer type.
  • WGD+ tumours showed reduced interferon-response and HLA antigen-presentation programmes.

All sections

Edition